Video claim watch

Unapproved Weight-Loss Drug 'Reta' Sold Online Despite Safety Concerns

A concise news report connects the nickname 'reta' to the real investigational drug and the safety questions around online availability.

CBS TEXAS channel3:45 runtime7.2K views when checked

Published Jun 8, 2026. Metadata checked Jul 10, 2026.

Watch on YouTube

Transcript review

6 material claims logged

Published with source gaps audit stateauto-captioned transcript0 operational-guidance flags2 source gaps

Reviewed Jul 12, 2026. Next review Aug 12, 2026.

strong investigation lead; claims about vendor counts and enforcement require document retention.

auto-caption available; no chapters.

Claim-by-claim audit

What the video says, and what needs checking

High-risk evidence claimHigh-risk commercial claim

Retatrutide is marketed online as suppressing hunger, reducing fat, and retaining muscle.

Review topic: retatrutide / social claims.

Checked against: Retatrutide phase 2 results: 24.2% weight loss (NEJM), Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.

“retain muscle” needs body-composition data, not testimonials.

High-risk regulatory claim

Retatrutide is still investigational and not FDA-approved.

Review topic: retatrutide / status.

Checked against: TRIUMPH-1: retatrutide in participants with obesity or overweight, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.

High-risk safety claimHigh-risk regulatory claim

CBS reports doctors offering it and a self-user reporting appetite effects, increased heart rate, insomnia, and three emergency-care visits.

Review topic: adverse-event signal / prescribing.

Checked against: Primary-source record still needed

trial safety tables plus any obtainable medical records; anecdote is not incidence evidence.

High-risk regulatory claimHigh-risk commercial claim

The investigation reports 125 medical vendors advertising access and at least 21 pages disappearing after inquiries.

Review topic: company/vendor enforcement.

Checked against: Warning Letter: Gram Peptides, Warning Letter: Xcel Research LLC

archive the CBS source packet/pages; compare R-RET-5 and R-RET-6.

High-risk regulatory claim

CBS says FDA had issued 14 warning letters since 2024.

Review topic: enforcement timeline.

Checked against: Primary-source record still needed

FDA warning-letter database; verify count and inclusion criteria before publishing.

High-risk regulatory claim

Lilly says consumer sale is unlawful; FDA says retatrutide has not been found safe/effective for any condition.

Review topic: sponsor / FDA status.

Checked against: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss., Warning Letter: Gram Peptides

Connected research

Compounds discussed

Retatrutide Retatrutide has produced large weight reductions in randomized Phase 2 and Phase 3 trials, but it remains unapproved. Long-term outcomes, direct comparisons, rare risks, durability, and final regulatory decisions remain unresolved.

Source check

Records used in this claim audit

Retatrutide for Obesity: A Phase 2 Trial

New England Journal of Medicine · Peer reviewed · Jun 26, 2023 · accessed Jul 1, 2026

Retatrutide phase 2 obesity trial (NEJM 2023): at 12 mg, mean body weight fell 17.5% at week 24 and 24.2% at week 48; GI adverse events were most common.

12 linked pagesOpen original · nejm-retatrutide-phase2-2023

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.

Eli Lilly and Company · Official company source · May 21, 2026 · accessed Jul 12, 2026

Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. News release, 2026-05-21.

9 linked pagesOpen original · research-reta-04

TRIUMPH-1: retatrutide in participants with obesity or overweight

ClinicalTrials.gov · Primary regulatory · Jul 3, 2023 · accessed Jul 12, 2026

Completed Phase 3 master protocol NCT05929066. The registry identifies TRIUMPH-1 as a randomized, double-blind, placebo-controlled study in adults without type 2 diabetes who have obesity or overweight.

12 linked pagesOpen original · clinicaltrials-retatrutide-triumph1

FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.

U.S. Food and Drug Administration · Primary regulatory · accessed Jul 12, 2026

U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Accessed 2026-07-12.

11 linked pagesOpen original · research-reta-02

Warning Letter: Gram Peptides

U.S. Food and Drug Administration · Primary regulatory · Mar 31, 2026 · accessed Jun 30, 2026

FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.

35 linked pagesOpen original · fda-gram-peptides-warning-2026

Warning Letter: Xcel Research LLC

U.S. Food and Drug Administration · Primary regulatory · Dec 10, 2024 · accessed Jul 12, 2026

FDA warning letter documenting agency findings about products marketed with research-use language.

2 linked pagesOpen original · fda-xcel-research-warning-2024